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knocked out speciﬁcally in cartilage (Col2a1Cre;Elf3ﬂ/ﬂ) or overex-
pressed in cartilage and synovium (ComptTA;TRE-Elf3) to analyze the
impact on OA initiation and progression. In this session, I will address
the in vitro and in vitro models that we use in our research to under-
stand how these mediators play pivotal roles in OA disease by coordi-
nating a complex, multilayered signaling network.
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PLACEBO RESPONSE: IT'S ROLE IN OA RESEARCH AND CLINICAL
PRACTICE
P. Dieppe. Univ. of Exeter, Exeter, United Kingdom
Purpose: To review recent research on placebo and nocebo of relevance
to osteoarthritis.
Methods: Literature reviews, psycho-physiological experiments,
recordings of patient-practitioner interactions, and qualitative inter-
views with people with pain and osteoarthritis.
Results: The placebo response is a purely artiﬁcial phenomenon: it is
the response seen to an inert, sham or dummy therapy administered as
a comparator to a tested intervention in the unreal, experimental
context of a clinical trial. It is poorly understood, and sometimes con-
sidered a ‘nuisance’ to trialists and those at the forefront of the evidence
based medicine movement. But it provides us with insights into one of
the most important phenomena in clinical medicine: the ability of
people to get symptomatically better without the use of any speciﬁc
intervention.
In trials of interventions designed to help people with osteoarthritis
(OA) we see large placebo responses, particularly for symptoms such as
pain and stiffness. In a systematic review/meta-analysis, the effect size
of placebos for OA symptoms was found to be around 0.5, which is
greater than that of many accepted interventions used. Injections have a
greater placebo effect than tablets, and trials using sham surgery have
shown that several surgical procedures used for people with OA, such as
arthroscopic washouts of the knee, are not superior to the sham
intervention. Clearly, a better understanding of what factors are
involved in producing a large placebo effect would help people trying to
assess new interventions for OA.
The placebo effect is seen in response to many different types of
intervention, and the symptoms (but probably not the pathology) of
many different diseases can respond to placebos used in clinical trials.
Some of the best research has come fromwork on models of acute pain,
on Parkinson’s disease and depression, and these disorders may be
better models than OA for the exploration of the psychological and
neurological mechanisms involved. Early research on mechanisms
concentrated on psychological factors: expectations and conditioning
were considered the key mechanisms, with other factors such as
anxiety (which can reduce the response) also involved. More recently
functional neuro-imaging and neurophysiological studies have come to
dominate the literature. It would seem that placebo analgesia may
involve activation of the descending inhibitory pathways of pain con-
trol, and be mediated, in part, by intrinsic opiods; however, there is
clearly heterogeneity within mechanisms as well as the clinical
responses. Other neurological theories have been postulated, including
activation of the polyvagal system and functional connectivity.
Clinicians trying to help people with OA need to consider all aspects of
the context in which they deliver care to people with OA, in order to
maximise the beneﬁt that can accrue from the non-speciﬁc (placebo)
aspects of their interventions. We have self-healing potential, and what
we discuss as a ‘placebo effect’ is a part of the even bigger, more
important phenomenon of activated self-healing of body mind and
spirit.
Attention has recently been re-drawn to the power of the placebo’s ‘evil
twin’ - the nocebo effect. It is clear that negative expectations and
anxiety can result in pain getting worse instead of better, and a recent
research report entitled ‘bad is more powerful than good’ cites the
psychological evidence that suggests that we are more susceptible to
negative inﬂuences on our bodies and minds than to positive ones.
Conclusions: Context (placebo) effects are a major component of the
symptomatic response of people with OA to conventional interventions.
However, many patient-practitioner interactions inadvertently result in
the opposite effect (a nocebo response). We need to learn how to use
the former to the advantage of our patients, and avoid the latter.I-8
ENDOGENOUS MECHANISMS AND PATHWAYS OF CARTILAGE
HEALING
F. Beier. Western Univ., London, ON, Canada
Cartilage degeneration is the major hallmark of osteoarthritis. The
repair and renewal capacity of articular cartilage has long been thought
to be extremely limited. However, recent evidence for endogenous
cartilage repair has cast doubt on this dogma. I will review recent lit-
erature on this process, the molecular mechanisms involved, and
potential factors inﬂuencing renewal capacity (age, genetic background
etc.). I will also focus on the pathways regulating development of
articular cartilage, with the underlying working model that manipu-
lation of these pathways is a promising strategy to promote growth and
repair of articular cartilage. In this context I will present our recent data
showing that cartilage-speciﬁc inactivation of the signaling molecule
Mig-6 in mice results in marked increases in articular cartilage thick-
ness and articular chondrocyte proliferation.
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CLINICAL DEFINITIONS OF EARLY OA: IMPLICATIONS FOR
PREVENTION
G. Peat. Keele Univ., Keele, United Kingdom
Advances in imaging and other biomarkers have been actively
extending knowledge on molecular and pre-radiographic stages of
osteoarthritis pathology. However, the interpretation of biomarkers
typically demands knowledge of their relationship to clinically impor-
tant states or events, either at the time of biomarker acquisition or in
the future. Therefore within this expanding view of the natural history
of osteoarthritis lies a set of complex challenges. Among these chal-
lenges are (i) to reﬂect on how and at what stage in the natural history
of the condition patients currently present to health services; (ii) to
elucidate the nature and timing of emergent signs and symptoms in
relation to biomarker-deﬁned disease states and their signiﬁcance for
future clinically important states and events.
Currently, if detection of OA is assumed to be the point of recorded
clinical diagnosis of OA in routine primary care, electronic health record
(EHR) database studies suggest that this occurs relatively late in the
pathological process, and varies substantially between individual
practitioners. This does not, however, fully capture when symptomatic
osteoarthritis ﬁrst presents nor when management begins. An unclear
proportion of osteoarthritis diagnoses are preceded by prior con-
sultations for joint symptoms labelled as non-speciﬁc problems. How-
ever, the longitudinal pattern of these prior consultations together with
other risk factor information held within the EHR may be exploited for
risk prediction algorithms. Qualitative studies of the osteoarthritis
consultation in primary care provide additional examples of symptoms
of OA presented as mere ‘fragments’ in the doctor-patient interaction or
as ‘door handle’ problems that remain off the record but which in
theory present opportunities for earlier recognition andmanagement of
OA. A critical issue is which of these presenting signs and symptoms are
of real prognostic signiﬁcance.
Findings from a series of population-based prospective observational
cohort studies provide evidence on several symptoms and signs
occurring in a pre-radiographic stage that can precede, and are asso-
ciated with an increased risk of, the incidence of frank structural
abnormality on plain radiographs. In recent analyses a possible pro-
dromal phase of increasing likelihood of symptoms among cases
developing incident radiographic OA has been described. However, the
ability of these early signs and symptoms to consistently identify
individuals with a high absolute risk of future clinically important states
and events cannot be assumed. A single irreversible transition into
progressive OA may not be the norm and extended periods of apparent
non-progressive symptoms and functional limitation have been repor-
ted. Furthermore, it remains possible that the majority of cases of
progressive or ultimately severely disabling cases arise not from the few
individuals classed as high risk but from the many classed as low-
medium risk (Rose’s prevention paradox).
